Holen Sie sich die Stockscreener-App
22.26
26.48%
4.66
Schlusskurs vom Vortag:
$17.60
Offen:
$18.37
24-Stunden-Volumen:
17.77M
Relative Volume:
8.92
Marktkapitalisierung:
$3.73B
Einnahmen:
$890.53M
Nettoeinkommen (Verlust:
$30.57M
KGV:
123.67
EPS:
0.18
Netto-Cashflow:
$80.53M
1W Leistung:
+27.64%
1M Leistung:
+52.78%
6M Leistung:
+32.74%
1J Leistung:
+49.90%
1-Tages-Spanne:
$18.37
$25.23
1-Wochen-Bereich:
$16.86
$25.23
52-Wochen-Spanne:
$13.40
$25.23
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Firmenname
Acadia Pharmaceuticals Inc
Sektor
Branche
Telefon
858-558-2871
Adresse
12830 EL CAMINO REAL, SAN DIEGO
Vergleichen Sie ACAD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
22.26 | 2.92B | 890.53M | 30.57M | 80.53M | 0.18 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2025-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-03-12 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-12 | Bestätigt | Needham | Buy |
| 2024-01-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-01-24 | Hochstufung | Needham | Hold → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-06 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-10-10 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-11-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-11-01 | Eingeleitet | Loop Capital | Hold |
| 2022-08-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-21 | Herabstufung | Jefferies | Buy → Underperform |
| 2022-06-16 | Hochstufung | Jefferies | Hold → Buy |
| 2022-03-16 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-21 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-06-10 | Eingeleitet | Berenberg | Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-04-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-04-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2021-03-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-11-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-07 | Hochstufung | Stifel | Hold → Buy |
| 2020-04-16 | Eingeleitet | Jefferies | Buy |
| 2020-03-31 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2019-12-16 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-01 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-09-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Bestätigt | Needham | Buy |
| 2018-12-10 | Eingeleitet | Canaccord Genuity | Hold |
| 2018-09-21 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-08-06 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
Acadia Pharmaceuticals secures patent protection for Parkinson’s drug By Investing.com - Investing.com Nigeria
Healthcare Stocks Lifted By Legal Wins And Drug Approvals - Finimize
Sector Update: Health Care - marketscreener.com
Acadia Pharmaceuticals secures patent protection for Parkinson’s drug - Investing.com Australia
Acadia Pharmaceuticals (ACAD) Wins Key Patent Case for Nuplazid - GuruFocus
Acadia Pharmaceuticals jumps after win in patent suit over Nuplazid - MSN
Acadia Pharmaceuticals (ACAD) Wins Key Patent Case for Nuplazid | ACAD Stock News - GuruFocus
Acadia (ACAD) Wins Patent Dispute, Secures Future Revenues | ACAD Stock News - GuruFocus
Delaware District Court Rules in Favor of Acadia in NUPLAZID® (p - GuruFocus
Acadia confirms court ruling in favor of Nuplazid formulation patent - TipRanks
Acadia Pharmaceuticals (ACAD) Wins Patent Infringement Case Agai - GuruFocus
Acadia Pharmaceuticals (ACAD) Sees Price Target Increase from Ne - GuruFocus
Acadia Pharma (ACAD) announces that Delaware Court has ruled in its favor for NUPLAZID litigation - StreetInsider
Delaware District Court Rules In Favor Of Acadia In Nuplazid Formulation Patent Litigation - marketscreener.com
Oppenheimer Raises Price Target for Acadia Pharmaceuticals (ACAD) | ACAD Stock News - GuruFocus
Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation - Business Wire
Acadia Wins Patent Ruling Over Aurobindo’s Nuplazid Copies (2) - Bloomberg Law News
Evolv Technologies, Quantum Computing, ACADIA Pharmaceuticals And Other Big Stocks Moving Higher On Friday - Benzinga
Acadia Pharmaceuticals (ACAD) Soars Following Patent Victory - GuruFocus
Acadia Pharmaceuticals (ACAD) Wins Patent Infringement Case | ACAD Stock News - GuruFocus
Acadia Pharmaceuticals shares surge on patent ruling - Investing.com
Acadia Pharmaceuticals jumps after win in patent suit over Nuplazid (ACAD:NASDAQ) - Seeking Alpha
Acadia Pharmaceuticals at BofA Conference: Strategic Growth Plans - Investing.com Australia
Acadia Pharmaceuticals at BofA Conference: Strategic Growth Plans By Investing.com - Investing.com India
Transcript : ACADIA Pharmaceuticals Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 03 - marketscreener.com
ACADIA Pharmaceuticals: Advancing On Several Fronts (NASDAQ:ACAD) - Seeking Alpha
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2025 Earnings Call Transcript - MSN
Acad projects $244.3M Q1 revenue with DAYBUE and NUPLAZID growth, anticipates accelerated Prader-Willi trial data - MSN
Acadia Pharmaceuticals files to sell 43.58M shares of common stock for holders - MSN
Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth - MSN
Investor Network: ACADIA Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Acadia Pharmaceuticals (ACAD) Prepares for Stock Sale by Shareho - GuruFocus
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised) - Yahoo Finance
Acadia Pharmaceuticals Inc Files For Offering Of Up To 43.6 Million Shares Of Common Stock By The Selling StockholdersSEC Filing - marketscreener.com
Acadia Pharmaceuticals (ACAD) Prepares for Stock Sale by Shareholders - GuruFocus
Acadia Pharma (ACAD) Files for 43.58M Share Offering by Selling Stockholders - StreetInsider
New Parkinson's Disease Therapies Market Outlook & Research - openPR.com
ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates - MSN
ACADIA Pharmaceuticals Reports Strong Q1 Earnings Growth - TipRanks
Schizophrenia Market Growth Projections 2024-2034: - openPR.com
Acadia: Q1 Earnings Snapshot - Norwalk Hour
Cautious Hold Rating on ACADIA Pharmaceuticals Amid Mixed Performance and Future Prospects - TipRanks
Acadia Pharmaceuticals Reports Strong Q1 2025 Growth - TipRanks
Earnings call transcript: Acadia Pharmaceuticals beats Q1 2025 forecasts By Investing.com - Investing.com Nigeria
Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview - BioSpace
ACADIA Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Acadia Pharmaceuticals Q1 2025 slides: revenue jumps 19%, pipeline timeline accelerated - Investing.com Canada
Neuren updates on first quarter 2025 US sales of Daybue - Biotech Dispatch
Earnings call transcript: Acadia Pharmaceuticals beats Q1 2025 forecasts - Investing.com
ACAD Q1 Revenue Surpasses Expectations, Reports Strong Patient Growth | ACAD Stock News - GuruFocus
Finanzdaten der Acadia Pharmaceuticals Inc-Aktie (ACAD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):